COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Interpersonal Psychotherapy for Severely Depressed Inpatients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00325000
Recruitment Status : Terminated
First Posted : May 11, 2006
Last Update Posted : December 20, 2006
Information provided by:
German Research Foundation

Brief Summary:
We examined the hypotheses that severely depressed inpatients treated for 5 weeks with IPT-S plus pharmacotherapy have 1) a higher reduction in depressive symptoms and 2) higher response- and remission rates compared to pharmacotherapy plus CM. For the follow-up period (12 months) we hypothesized a better symptomatic and psychosocial longterm outcome and lower rates of relapse for patients initially treated with combination therapy.

Condition or disease Intervention/treatment Phase
Major Depression Behavioral: Interpersonal Psychotherapy Drug: sertraline or amitriptyline Not Applicable

Detailed Description:
A randomized controlled trial was conducted in 124 hospitalized patients with a DSM IV diagnosis of Major Depressive Disorder comparing 5 weeks of Interpersonal Psychotherapy modified for depressed inpatients (IPT-S) plus pharmacotherapy versus medication plus intensive Clinical Management (CM). The study included a prospective, naturalistic follow-up 3- and 12 months after acute treatment in 97 of 105 treatment completers. The 17-item version of the Hamilton Rating Scale for Depression (HAMD) served as the primary outcome measure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Severely Depressed Inpatients
Study Start Date : November 2000
Study Completion Date : August 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. The 17-item version of the Hamilton Rating Scale for Depression (HAMD) served as the primary outcome measure

Secondary Outcome Measures :
  1. Beck Depression Inventory

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Major Depression (single episode, recurrent or bipolar II) according to the Structured Clinical Interview for DSM IV (SCID)and a score of ≥ 16 on the 17-item version of the Hamilton Rating Scale for Depression (HAMD)

Exclusion Criteria:

(1) concurrent diagnosis of bipolar I disorder, primary substance abuse or dependency, mental disorder due to organic factors, and borderline or antisocial personality disorder, (2) psychotic symptoms, (3) severe cognitive impairment, (4) contraindications to the study medication, and (5) being actively suicidal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00325000

Layout table for location information
University Clinic Freiburg , Dept. of Psychiatry and Psychotherapy
Freiburg, Germany, 79104
Sponsors and Collaborators
German Research Foundation
Layout table for investigator information
Study Director: Mathias Berger, MD University Clinic Freiburg, Dept. of Psychiatry and Psychotherapy
Layout table for additonal information Identifier: NCT00325000    
Other Study ID Numbers: SCHR443/4-1
First Posted: May 11, 2006    Key Record Dates
Last Update Posted: December 20, 2006
Last Verified: October 2000
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder, Major
Depressive Disorder
Mood Disorders
Mental Disorders
Amitriptyline, perphenazine drug combination
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Tricyclic
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic Uptake Inhibitors
Adrenergic Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants